NASDAQ · AUTL
Healthcare · Biotechnology
$1.96
Down-$0.07 (-3.45%)
Updated Sep 11, 2026, 5:02 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AUTL closed at $1.96 after 20 trading sessions, down 11.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $2.00 | $2.02 | $1.95 | $1.96 | 1.33M |
| Sep 9, 2026 | $2.10 | $2.10 | $2.02 | $2.03 | 1.72M |
| Sep 8, 2026 | $2.22 | $2.23 | $2.10 | $2.11 | 2.57M |
| Sep 4, 2026 | $2.31 | $2.31 | $2.22 | $2.24 | 1.84M |
| Sep 3, 2026 | $2.26 | $2.325 | $2.255 | $2.29 | 1.91M |
| Sep 2, 2026 | $2.32 | $2.375 | $2.22 | $2.24 | 2.31M |
| Sep 1, 2026 | $2.31 | $2.38 | $2.30 | $2.31 | 1.48M |
| Aug 31, 2026 | $2.315 | $2.38 | $2.295 | $2.35 | 1.2M |
| Aug 28, 2026 | $2.35 | $2.36 | $2.28 | $2.34 | 1.44M |
| Aug 27, 2026 | $2.32 | $2.42 | $2.305 | $2.36 | 1.23M |
| Aug 26, 2026 | $2.41 | $2.42 | $2.315 | $2.33 | 1.43M |
| Aug 25, 2026 | $2.38 | $2.45 | $2.36 | $2.44 | 1.52M |
| Aug 24, 2026 | $2.40 | $2.405 | $2.31 | $2.34 | 1.22M |
| Aug 21, 2026 | $2.47 | $2.51 | $2.40 | $2.41 | 2.41M |
| Aug 20, 2026 | $2.47 | $2.525 | $2.43 | $2.46 | 3.25M |
| Aug 19, 2026 | $2.36 | $2.58 | $2.33 | $2.54 | 7.84M |
| Aug 18, 2026 | $2.25 | $2.345 | $2.215 | $2.29 | 3.36M |
| Aug 17, 2026 | $2.15 | $2.33 | $2.13 | $2.28 | 3.04M |
| Aug 14, 2026 | $2.22 | $2.24 | $2.04 | $2.15 | 2.4M |
| Aug 13, 2026 | $2.12 | $2.2691 | $2.06 | $2.22 | 2.24M |
The latest Smart Investors Daily articles mentioning AUTL.
AUTL research
Company profile and research snapshot.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 9, 2026 | Needham | Buy | — |
| Mar 31, 2026 | Mizuho | Outperform | — |
| Mar 27, 2026 | Needham | Buy | — |
Generated Sep 10, 2026, 9:06 PM
Autolus Therapeutics shares declined 3.45% despite receiving positive regulatory recognition for its lead candidate. The FDA's grant of Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel for systemic lupus erythematosus and lupus nephritis represents a meaningful milestone, yet the market's muted-to-negative reaction suggests investors may be pricing in execution risks or have high expectations already embedded in the stock.
Bottom line: While the RMAT designation is genuinely positive for Autolus' long-term development timeline, today's decline highlights that regulatory process advantages alone don't guarantee investment success—clinical efficacy data and commercial viability remain the true catalysts investors are awaiting. Shareholders should monitor upcoming clinical updates and consider this a measured opportunity for patient capital, with clear risks around execution and competition.
Benzinga · Sep 9, 2026
The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026. LUMINA, the
SeekingAlpha · Aug 11, 2026
2026-08-11. The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2026 Q2 earnings call.
SeekingAlpha · Aug 11, 2026
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call August 11, 2026 8:30 AM EDTCompany ParticipantsAmanda Cray - Executive Director of Investor Relations...
Benzinga · Aug 11, 2026
Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AUTL.
